| Fedratinib in Combination With Nivolumab (NCT05393674) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-06-14 |
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib (NCT05280509) | Telios Pharma, Inc. | 2022-06-09 |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (NCT05320198) | Disc Medicine, Inc | 2022-06-06 |
| Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera (NCT06516406) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-05-06 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) (NCT05223920) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2021-12-15 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (NCT04551053) | Incyte Corporation | 2021-05-26 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) (NCT04551066) | Incyte Corporation | 2021-05-24 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (NCT04603495) | Novartis Pharmaceuticals | 2021-04-09 |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (NCT04896112) | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (NCT04717414) | Celgene | 2021-02-25 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (NCT04243122) | Ottawa Hospital Research Institute | 2021-02-17 |
| Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis (NCT04517851) | M.D. Anderson Cancer Center | 2021-02-10 |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (NCT04370301) | Fred Hutchinson Cancer Center | 2021-02-09 |
| Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (NCT04384692) | Fred Hutchinson Cancer Center | 2020-12-18 |
| Study of Select Combinations in Adults With Myelofibrosis (NCT04283526) | Novartis Pharmaceuticals | 2020-11-30 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF (NCT04640532) | Kartos Therapeutics, Inc. | 2020-11-17 |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (NCT04339101) | City of Hope Medical Center | 2020-11-11 |
| A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) (NCT04446650) | Bristol-Myers Squibb | 2020-10-12 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) (NCT04173494) | Sierra Oncology LLC - a GSK company | 2020-02-07 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03952039) | Celgene | 2019-09-09 |
| PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis (NCT04054245) | M.D. Anderson Cancer Center | 2019-07-24 |
| Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (NCT03627403) | University of Utah | 2019-05-10 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03755518) | Celgene | 2019-03-27 |
| MPN-RC 118 AVID200 in Myelofibrosis (NCT03895112) | John Mascarenhas | 2019-02-15 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis (NCT03373877) | Samus Therapeutics, Inc. | 2018-05-24 |
| Extended Access of Momelotinib in Adults With Myelofibrosis (NCT03441113) | GlaxoSmithKline | 2018-05-03 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis (NCT03303950) | University of Utah | 2018-03-30 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (NCT03426969) | M.D. Anderson Cancer Center | 2018-01-31 |
| A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence (NCT03194542) | Celgene | 2017-11-15 |
| Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib (NCT04884191) | CTI BioPharma | 2017-07-31 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (NCT03165734) | Swedish Orphan Biovitrum | 2017-06-26 |
| PD-1 Inhibition in Advanced Myeloproliferative Neoplasms (NCT03065400) | John Mascarenhas | 2017-06-14 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms (NCT06371573) | Federico II University | 2017-04-20 |
| Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (NCT02966353) | Novartis Pharmaceuticals | 2017-03-31 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis (NCT02917096) | City of Hope Medical Center | 2016-11-13 |
| Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (NCT02871323) | Northwestern University | 2016-11-01 |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (NCT02805868) | Northwestern University | 2016-06-01 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT (NCT02728700) | Stanford University | 2016-02-01 |
| PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis (NCT02806375) | St. Petersburg State Pavlov Medical University | 2016-01-01 |
| A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis (NCT02584777) | Baxalta now part of Shire | 2015-11-30 |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis (NCT02528877) | City of Hope Medical Center | 2015-11-01 |
| Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia (NCT02530619) | Northwestern University | 2015-10-09 |
| Myeloproliferative Neoplastic Diseases Observatory From Brest (NCT02897297) | University Hospital, Brest | 2015-09-01 |
| P1101 in Treating Patients With Myelofibrosis (NCT02370329) | Mayo Clinic | 2015-08-12 |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis (NCT02421354) | M.D. Anderson Cancer Center | 2015-05-14 |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation (NCT02311569) | Swiss Cancer Institute | 2015-04-01 |
| Myeloproliferative Neoplasms (MPNs) Patient Registry (NCT02760238) | University Health Network, Toronto | 2015-04-01 |
| CINC424A2X01B Rollover Protocol (NCT02386800) | Novartis Pharmaceuticals | 2015-03-05 |
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis (NCT02098161) | M.D. Anderson Cancer Center | 2014-12-18 |
| JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (NCT02251821) | Fred Hutchinson Cancer Center | 2014-10-20 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (NCT02129101) | Mayo Clinic | 2014-05-01 |
| Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (NCT02124746) | Sierra Oncology LLC - a GSK company | 2014-04-30 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (NCT02055781) | CTI BioPharma | 2014-02-01 |
| Connect® Myeloid Disease Registry (NCT01688011) | Celgene | 2013-12-12 |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (NCT01969838) | Sierra Oncology LLC - a GSK company | 2013-12-06 |
| Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (NCT01790295) | John Mascarenhas | 2013-11-01 |
| A Phase 2 Study of RO7490677 In Participants With Myelofibrosis (NCT01981850) | Hoffmann-La Roche | 2013-10-01 |
| Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (NCT01644110) | University of Ulm | 2013-08-01 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF (NCT01787552) | Novartis Pharmaceuticals | 2013-05-08 |
| Myeloproliferative Neoplasms: an In-depth Case-control Study (NCT01831635) | Queen's University, Belfast | 2013-04-01 |
| Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (NCT01732445) | Mayo Clinic | 2013-04-01 |
| Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT01787487) | M.D. Anderson Cancer Center | 2013-03-13 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis (NCT01773187) | CTI BioPharma | 2013-01-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (NCT01731951) | Geron Corporation | 2012-10-29 |
| A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis (NCT05044026) | Novartis Pharmaceuticals | 2012-09-20 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Myeloproliferative Neoplasms and Bone Structure (NCT01816022) | University of Southern Denmark | 2012-03-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (NCT01387763) | Thomas Stauffer Larsen | 2012-01-01 |
| A Phase 2 Study With IPI-926 in Patients With Myelofibrosis (NCT01371617) | Infinity Pharmaceuticals, Inc. | 2011-10-01 |
| Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis (NCT01445769) | Incyte Corporation | 2011-09-01 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (NCT01423058) | Sierra Oncology LLC - a GSK company | 2011-08-01 |
| Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis (NCT01331603) | Wolfson Medical Center | 2011-03-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Anti-TGF-beta Therapy in Patients With Myelofibrosis (NCT01291784) | John Mascarenhas | 2011-02-01 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (NCT01236638) | Sierra Oncology LLC - a GSK company | 2010-11-01 |
| Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (NCT01178281) | Celgene | 2010-09-08 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| A Study in Myeloproliferative Disorders (NCT01134120) | Eli Lilly and Company | 2010-04-01 |
| LBH589 (Panobinostat) for the Treatment of Myelofibrosis (NCT01298934) | Ronald Hoffman | 2009-09-01 |
| A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis (NCT00931762) | Novartis Pharmaceuticals | 2009-08-31 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) | National Cancer Institute (NCI) | 2006-09-01 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia (NCT00381550) | National Cancer Institute (NCI) | 2006-08-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |